Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 2/20 | 0.37 |
| ▸ | DUT | P33316 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.33 |
| ▸ | BCL2 | P10415 | 5/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.32 |
| ▸ | BAD | Q92934 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6394349 | 0.84 | RAB9A (0.41) | ACLYMCL1HTR2AHTR2CBCL2L1 | |
| SCHEMBL6395794 | 0.80 | ACLY (0.35) | ACLY | |
| SCHEMBL6402171 | 0.78 | ACLY (0.37) | ACLYMCL1BCL2NR1H2PPARA | |
| SCHEMBL6260801 | 0.77 | DUT (0.52) | ACLYDUTMCL1BCL2HTR2A | |
| SCHEMBL6400589 | 0.76 | KMO (0.44) | ACLYMCL1BCL2L1BAD | |
| SCHEMBL4417971 | 0.75 | ELANE (0.40) | — | |
| SCHEMBL6402252 | 0.73 | ELANE (0.43) | MCL1BCL2L1BAD | |
| SCHEMBL6394753 | 0.73 | HTR7 (0.38) | ACLYMCL1 | |
| SCHEMBL6398448 | 0.72 | MEN1 (0.48) | MCL1NR1H2PPARANR1H3HTR2A | |
| SCHEMBL6393899 | 0.72 | MCL1 (0.40) | MCL1BCL2L1BAD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | EXONHIT THERAPEUTICS SA (FR) | 2005-03-10 | — | — | US | disclosed |
| EP-1480966-A1 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES | Exonhit Therapeutics S.A. (FR) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074508-A1 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES | EXONHIT THERAPEUTICS SA (FR) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | MKI67, CCNC, PCNA | ACLY 1178/4885DUT 141/4885MCL1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.